Analyst consensus rating
Relay Therapeutics Analyst Rating: Strong Buy
RLAY is rated Strong Buy by 13 analysts with a $27.08 target. As of 2026-08-28.
Direct answer
Relay Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $27.08.
Forecast evidence checked August 28, 2026.
Get free Relay Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $18.73
- Average price target
- $27.08
- High price target
- $32.00
- Low price target
- $20.00
- Low target gap
- +6.8%
- Target upside
- +44.6%
- High target gap
- +70.9%
- Target range width
- 64.1%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Relay Therapeutics?
Relay Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $27.08.
How far are Relay Therapeutics's low and high targets from the recorded price?
The low target implies +6.8%, while the high target implies +70.9%.
How many analysts are included in Relay Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Relay Therapeutics's target upside or downside calculated?
The average target of $27.08 is divided by the recorded price of $18.73, then one is subtracted to produce +44.6%. This does not guarantee a future return.
When was Relay Therapeutics's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.